On June 20, 2024, Michael A. Choti, MD, MBA, Banner MD Anderson, co-chaired the second annual Advancing Worth-Primarily based Oncology Care assembly in Phoenix, Arizona. In an interview with The American Journal of Managed Care®, Choti touched upon the targets of this 12 months’s occasion, in addition to among the essential challenges and issues of value-based oncology care.
This transcript has been calmly edited
Transcript
How would you characterize the targets of, or largest takeaways from, this second annual Advancing Worth-Primarily based Oncology Care occasion?
Oncology is difficult. It is costly, it requires integration. I believe a message right here that we have discovered is de facto the significance of the complexity of [value-based care], of managing most cancers care in an built-in means, controlling prices. So, this assembly actually highlighted how others are doing it. At Banner MD Anderson, we’re a company that is clearly shifting in that path; we showcased the path that we’re entering into on this area, and I believe it actually made for a really thrilling symposium once more this 12 months.
In your opinion, what are essentially the most vital elements that must be in place for value-based oncology care to be efficiently carried out?
The vital elements to maneuver towards value-based care, as you’ve got heard on this convention as nicely, is de facto the creation of built-in multidisciplinary most cancers administration; informatics and good analytics to be able to actually perceive value, utilization, finest follow; in addition to alternatives to deal with disparities and care for everybody.
How can well being care techniques stability the price of revolutionary most cancers therapies with the ideas of value-based care?
I believe one of many challenges of most cancers care is de facto balancing the price of most cancers care with the ideas of value-based medication. This can be a problem. How can we tackle this, and what are the methods we are able to? I believe one is to leverage applied sciences: predictive analytics, info expertise. Synthetic intelligence, I believe this will likely be an space that may help the path of offering high-quality most cancers care within the context of value-based care.
